An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation
A number of unexplained cases of pneumonia have been recorded since November 2019 in China. It is officially named the new corona virus (2019-nCov) by the World Health Organization on 12 January 2020. WHO officially named it COVID-19 on 11 February. COVID-19 is a highly transmitted and pathogenic vi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-02-01
|
| Series: | Journal of Infection and Public Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034120307759 |
| _version_ | 1818580221483286528 |
|---|---|
| author | P. Parthasarathy S. Vivekanandan |
| author_facet | P. Parthasarathy S. Vivekanandan |
| author_sort | P. Parthasarathy |
| collection | DOAJ |
| description | A number of unexplained cases of pneumonia have been recorded since November 2019 in China. It is officially named the new corona virus (2019-nCov) by the World Health Organization on 12 January 2020. WHO officially named it COVID-19 on 11 February. COVID-19 is a highly transmitted and pathogenic viral infection that has been developed and spread across the world in Wuhan, China, caused by extreme acute respiratory syndrome corona-virus 2 (SARS-CoV-2). Genomic analysis showed that bats may also be a primary reservoir of SARS-CoV-2 phylogenetically associated with severe acute respiratory syndrome-like viruses (SARS). However, the rapid human to human transition has been generally reported. Intermediate source of origin and human transition is unknown. Clinically approved COVID-19 antiviral medication or vaccine is not available. In clinical trials, however, few broad-based COVID-19 antiviral medicinal drugs were tested, resulting in clinical recovery. This analysis summarizes the pathogenicity of COVID-19 and aims to raise awareness of COVID-19 among the population and to continually boost the detection, monitoring, diagnosis and care level. Over 50 COVID-19 scientific publications were included in this systematic analysis. We found that fever (87.0%), cough (65.9%) and malaise/tiredness (35%) were the most common symptoms of COvida-19. However, COVID-19 clinical signs and symptoms were not necessarily obvious. The transmission of COVID-19 in comparison to SARS was more specific. The rate of death of COVID-19 was 2,7% and the pathological characteristics of COVID-19 are very similar to ARDS. There are also discussions on the latest epidemiological changes, clinical manifestations, auxiliary examination and COVID-19 pathological characteristics. |
| first_indexed | 2024-12-16T07:14:09Z |
| format | Article |
| id | doaj.art-d61da169ec5849438e9cef7da4a7839c |
| institution | Directory Open Access Journal |
| issn | 1876-0341 |
| language | English |
| last_indexed | 2024-12-16T07:14:09Z |
| publishDate | 2021-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Infection and Public Health |
| spelling | doaj.art-d61da169ec5849438e9cef7da4a7839c2022-12-21T22:39:50ZengElsevierJournal of Infection and Public Health1876-03412021-02-01142249259An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigationP. Parthasarathy0S. Vivekanandan1Corresponding author.; School of Electrical Engineering, VIT University, Tamilnadu, IndiaSchool of Electrical Engineering, VIT University, Tamilnadu, IndiaA number of unexplained cases of pneumonia have been recorded since November 2019 in China. It is officially named the new corona virus (2019-nCov) by the World Health Organization on 12 January 2020. WHO officially named it COVID-19 on 11 February. COVID-19 is a highly transmitted and pathogenic viral infection that has been developed and spread across the world in Wuhan, China, caused by extreme acute respiratory syndrome corona-virus 2 (SARS-CoV-2). Genomic analysis showed that bats may also be a primary reservoir of SARS-CoV-2 phylogenetically associated with severe acute respiratory syndrome-like viruses (SARS). However, the rapid human to human transition has been generally reported. Intermediate source of origin and human transition is unknown. Clinically approved COVID-19 antiviral medication or vaccine is not available. In clinical trials, however, few broad-based COVID-19 antiviral medicinal drugs were tested, resulting in clinical recovery. This analysis summarizes the pathogenicity of COVID-19 and aims to raise awareness of COVID-19 among the population and to continually boost the detection, monitoring, diagnosis and care level. Over 50 COVID-19 scientific publications were included in this systematic analysis. We found that fever (87.0%), cough (65.9%) and malaise/tiredness (35%) were the most common symptoms of COvida-19. However, COVID-19 clinical signs and symptoms were not necessarily obvious. The transmission of COVID-19 in comparison to SARS was more specific. The rate of death of COVID-19 was 2,7% and the pathological characteristics of COVID-19 are very similar to ARDS. There are also discussions on the latest epidemiological changes, clinical manifestations, auxiliary examination and COVID-19 pathological characteristics.http://www.sciencedirect.com/science/article/pii/S1876034120307759Corona virusCOVID-19Antiviral medicinal drugsPathological characteristicsEpidemiological characteristics |
| spellingShingle | P. Parthasarathy S. Vivekanandan An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation Journal of Infection and Public Health Corona virus COVID-19 Antiviral medicinal drugs Pathological characteristics Epidemiological characteristics |
| title | An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation |
| title_full | An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation |
| title_fullStr | An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation |
| title_full_unstemmed | An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation |
| title_short | An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation |
| title_sort | extensive study on the covid 19 pandemic an emerging global crisis risks transmission impacts and mitigation |
| topic | Corona virus COVID-19 Antiviral medicinal drugs Pathological characteristics Epidemiological characteristics |
| url | http://www.sciencedirect.com/science/article/pii/S1876034120307759 |
| work_keys_str_mv | AT pparthasarathy anextensivestudyonthecovid19pandemicanemergingglobalcrisisriskstransmissionimpactsandmitigation AT svivekanandan anextensivestudyonthecovid19pandemicanemergingglobalcrisisriskstransmissionimpactsandmitigation AT pparthasarathy extensivestudyonthecovid19pandemicanemergingglobalcrisisriskstransmissionimpactsandmitigation AT svivekanandan extensivestudyonthecovid19pandemicanemergingglobalcrisisriskstransmissionimpactsandmitigation |